Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Safety lead-in Randomized Blind Placebo-controlled Clinical Trial: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia in Adjunction of Conventional Systemic Antifungal Therapy

NCT06892951 is registered in ClinicalTrials.gov with University Hospital, Tours as lead sponsor.

NCT NCT06892951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06892951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Safety lead-in Randomized Blind Placebo-controlled Clinical Trial: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia in Adjunction of Conventional Systemic Antifungal Therapy
Lead sponsor
University Hospital, Tours
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 2, 2025
Completion date
December 31, 2028
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pneumocystis infections, pneumocystis jirovecii infection, pneumocystis pneumonia